1150 - Resistance Analysis in the COMET-TAIL Study: Participants with Mild-to-Moderate COVID-19 Treated with Intramuscular or Intravenous Sotrovimab

Friday, October 21, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

GS

Gretja Schnell, PhD

Vir Biotechnology, Inc.
San Francisco, California, United States
Jd

Julia di Iulio, PharmD, PhD, MBA

Vir Biotechnology, Inc.
San Francisco, California, United States
AK

Anita Kohli, MD

Arizona Liver Health
Tucson, Arizona, United States
Adrienne E. Shapiro, MD, PhD

Assistant Professor
University of Washington and Fred Hutchinson Cancer Center
Seattle, Washington, United States
ES

Elias H. Sarkis, MD

Sarkis Clinical Trials
Gainesville, Florida, United States
DI

Dave Inman, MSc

GlaxoSmithKline
Middlesex, England, United Kingdom
AP

Amanda Peppercorn, MD

GlaxoSmithKline
Cambridge, Massachusetts, United States
AS

Andrew Skingsley, MD

GlaxoSmithKline
Brentford, England, United Kingdom
LG

Leah A. Gaffney, PhD

Vir Biotechnology, Inc.
San Francisco, California, United States
MA

Melissa Aldinger, PharmD

Vir Biotechnology, Inc.
San Francisco, California, United States
CH

Christy M. Hebner, PhD

Vice President
Vir Biotechnology, Inc.
San Francisco, California, United States
AC

Andrea L. Cathcart, PhD

Vir Biotechnology, Inc.
San Francisco, California, United States